SCHEMBL23927059

SCHEMBL23927059

Nc1cnccc1Nc1ccc(Cl)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
PIK3CA P42336 2/20 0.40
GRM4 Q14833 1/20 0.40
GAA P10253 1/20 0.39
PTGS1 P23219 2/20 0.38
PTGS2 P35354 2/20 0.38
TNF P01375 1/20 0.38
CYP2A6 P11509 1/20 0.38
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
PIK3CD O00329 2/20 0.36
MAPK14 Q16539 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
SRC P12931 1/20 0.36
KCNQ3 O43525 2/20 0.36
KCNQ2 O43526 2/20 0.36
KCNE1 P15382 1/20 0.36
KCNQ1 P51787 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079505 1.00 LMNA (0.42) LMNAPIK3CAGRM4GAAPTGS1
SCHEMBL16657388 0.81 LMNA (0.60) LMNAGAAPTGS1PTGS2
SCHEMBL30079760 0.80 MAPT (0.55) LMNAPIK3CAGRM4GAAALDH1A1
SCHEMBL9994879 0.80 MAPT (0.55) LMNAPIK3CAGRM4GAAALDH1A1
SCHEMBL16089616 0.78 RAB9A (0.56) LMNAPTGS1PTGS2ALDH1A1HTT
SCHEMBL29582234 0.77 KDM1A (0.45) LMNAPIK3CAPTGS1PTGS2ALDH1A1
SCHEMBL14003573 0.77 RAD52 (0.52) LMNAGAAPTGS1PTGS2ALDH1A1
SCHEMBL16089612 0.76 TDO2 (0.49) LMNAGAAPTGS1PTGS2ALDH1A1
SCHEMBL23618943 0.75 TNF (0.37) PIK3CAGRM4TNFPIK3CDSRC
SCHEMBL23927051 0.75 ALDH1A1 (0.68) LMNAGAAALDH1A1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-4139306-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2023-03-01 EP disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed
WO-2021214090-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 LMNA 2149/4885PIK3CA 2780/4885GRM4 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.